Predict your next investment

Actuate Therapeutics company logo
HEALTHCARE | Drug Development
actuatetherapeutics.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series B - III | Alive

Total Raised

$50.27M

Last Raised

$14.48M | 1 yr ago

About Actuate Therapeutics

Actuate Therapeutics focuses on the development of compounds for combination use in high impact carcinomas including glioblastoma, ovarian, breast, and pancreatic cancers. The company has completed studies of its lead compound, 9-ING-41, in preclinical models of cancers, including both drug sensitive and drug resistant glioblastoma, results of which are quite compelling, including complete regressions of disease (cures) and significant increases in overall survival.

Actuate Therapeutics Headquarter Location

1751 River Run Suite 400

Fort Worth, Texas, 76107,

United States

817-984-5964

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Actuate Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Actuate Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Actuate Therapeutics Patents

Actuate Therapeutics has filed 4 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Amines
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/10/2018

10/5/2021

Experimental cancer drugs, Neurotrauma, Amines, Fluoroarenes, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/10/2018

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/5/2021

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Experimental cancer drugs, Neurotrauma, Amines, Fluoroarenes, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Actuate Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Actuate Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.